BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 28727946)

  • 1. Confounding by Single Nucleotide Polymorphism rs117648444 (P70S) Affects the Association of Interferon Lambda Locus Variants with Response to Interferon-α-Ribavirin Therapy in Patients with Chronic Genotype 3 Hepatitis C Virus Infection.
    Bhushan A; Ghosh S; Bhattacharjee S; Chinnaswamy S
    J Interferon Cytokine Res; 2017 Aug; 37(8):369-382. PubMed ID: 28727946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying causal variants at the interferon lambda locus in case-control studies: Utilizing non-synonymous variant rs117648444 to probe the role of IFN-λ4.
    Bhushan A; Chinnaswamy S
    Gene; 2018 Jul; 664():168-180. PubMed ID: 29705128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IFNL4 rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients.
    Galmozzi E; Facchetti F; Grossi G; Loglio A; Viganò M; Lunghi G; Colombo M; Lampertico P
    Liver Int; 2018 Mar; 38(3):417-423. PubMed ID: 28732143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-λ4 is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden.
    Lu YF; Goldstein DB; Urban TJ; Bradrick SS
    Virology; 2015 Feb; 476():334-340. PubMed ID: 25577150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting.
    Wiegand SB; Heidrich B; Susser S; Rogalska-Taranta M; Petersen J; Böker KH; Grigorian N; Link R; Naumann U; John C; Lueth S; Malfertheiner P; Manns MP; Wedemeyer H; Sarrazin C; Cornberg M
    PLoS One; 2015; 10(12):e0145622. PubMed ID: 26699619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.
    O'Brien TR; Pfeiffer RM; Paquin A; Lang Kuhs KA; Chen S; Bonkovsky HL; Edlin BR; Howell CD; Kirk GD; Kuniholm MH; Morgan TR; Strickler HD; Thomas DL; Prokunina-Olsson L
    J Hepatol; 2015 Nov; 63(5):1103-10. PubMed ID: 26186989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
    Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
    Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.
    Susser S; Herrmann E; Lange C; Hamdi N; Müller T; Berg T; Perner D; Zeuzem S; Sarrazin C
    PLoS One; 2014; 9(11):e112592. PubMed ID: 25393304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.
    Haj-Sheykholeslami A; Keshvari M; Sharafi H; Pouryasin A; Hemmati K; Mohammadzadehparjikolaei F
    World J Gastroenterol; 2015 Aug; 21(29):8935-42. PubMed ID: 26269684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.
    Stättermayer AF; Strassl R; Maieron A; Rutter K; Stauber R; Strasser M; Beinhardt S; Datz C; Scherzer TM; Steindl-Munda P; Gschwantler M; Trauner M; Hofer H; Ferenci P
    Aliment Pharmacol Ther; 2014 Jan; 39(1):104-11. PubMed ID: 24205831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IFNL4 ss469415590 polymorphism contributes to treatment decisions in patients with chronic hepatitis C virus genotype 1b, but not 2a, infection.
    Wu R; Chi X; Wang X; Sun H; Lv J; Gao X; Yu G; Kong F; Xu H; Hua R; Jiang J; Sun B; Zhong J; Pan Y; Niu J
    Infect Genet Evol; 2016 Apr; 39():132-140. PubMed ID: 26820907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.
    Murakawa M; Asahina Y; Kawai-Kitahata F; Nakagawa M; Nitta S; Otani S; Nagata H; Kaneko S; Asano Y; Tsunoda T; Miyoshi M; Itsui Y; Azuma S; Kakinuma S; Tanaka Y; Iijima S; Tsuchiya K; Izumi N; Tohda S; Watanabe M
    J Med Virol; 2017 Jul; 89(7):1241-1247. PubMed ID: 28036111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphism rs368234815 of interferon lambda 4 gene and spontaneous clearance of hepatitis C virus in haemodialysis patients: a case-control study.
    Grzegorzewska AE; Mostowska A; Świderska MK; Marcinkowski W; Stolarek I; Figlerowicz M; Jagodziński PP
    BMC Infect Dis; 2021 Jan; 21(1):102. PubMed ID: 33482747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single nucleotide polymorphism, rs129679860, in the IL28B locus is associated with the viral kinetics and a sustained virological response in a chronic, monoinfected hepatitis C virus genotype-1 Brazilian population treated with pegylated interferon-ribavirin.
    Ramos JA; Ramos AL; Hoffmann L; Perez Rde M; Coelho HS; Urményi TP; Silva R; Rondinelli E; Villela-Nogueira CA
    Mem Inst Oswaldo Cruz; 2012 Nov; 107(7):888-92. PubMed ID: 23147144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between IFNL4 rs368234815 polymorphism and sustained virological response in chronic hepatitis C patients undergoing PEGylated interferon/ribavirin therapy: A meta-analysis.
    Xie X; Zhang L; Chen YZ
    Hum Immunol; 2016 Jul; 77(7):609-15. PubMed ID: 27180197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
    World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon α Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection.
    Ali FT; Ali MA; Elgizawy MM; Elsawy AM
    Gut Liver; 2015 Jul; 9(4):516-24. PubMed ID: 25717047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant.
    Konishi H; Motomura T; Matsumoto Y; Harimoto N; Ikegami T; Yoshizumi T; Soejima Y; Shirabe K; Fukuhara T; Maehara Y
    J Viral Hepat; 2014 Jun; 21(6):397-404. PubMed ID: 24750545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
    Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
    Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.